Bionano Genomics stockholders approve reverse stock split (1:25-1:75) and warrant share issuance

Bionano Genomics, Inc.

At Jan 15 special meeting, stockholders approved issuance of up to 19,762,226 shares upon exercise of Series C/D warrants.
Proposal 2 approved reverse stock split at ratio between 1-for-25 and 1-for-75, with exact ratio to be set by Board.
Approvals required for Nasdaq listing compliance and to maintain stock price above minimum bid.
Votes: Proposal 1 – 7.1M for, 3.3M against, 6.7M abstain, 25.3M broker non-votes.
Votes: Proposal 2 – 29.0M for, 12.8M against, 0.6M abstain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.